Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue: 2024-2025

Historic Non-Current Deffered Revenue for Collegium Pharmaceutical (COLL) over the last 1 years, with Sep 2025 value amounting to $9.3 million.

  • Collegium Pharmaceutical's Non-Current Deffered Revenue fell 7.22% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 7.22%. This contributed to the annual value of $10.0 million for FY2024, which is N/A change from last year.
  • Per Collegium Pharmaceutical's latest filing, its Non-Current Deffered Revenue stood at $9.3 million for Q3 2025, which was down 7.22% from $10.0 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Non-Current Deffered Revenue peaked at $10.0 million during Q3 2024, and registered a low of $9.3 million during Q3 2025.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $10.0 million (2025), whereas its average is $9.9 million.
  • Data for Collegium Pharmaceutical's Non-Current Deffered Revenue shows a maximum YoY dropped of 7.22% (in 2025) over the last 5 years.
  • Over the past 2 years, Collegium Pharmaceutical's Non-Current Deffered Revenue (Quarterly) stood at $10.0 million in 2024, then fell by 7.22% to $9.3 million in 2025.
  • Its Non-Current Deffered Revenue was $9.3 million in Q3 2025, compared to $10.0 million in Q2 2025 and $10.0 million in Q1 2025.